BLUE News & Events

PepGen (PEPG) announced the appointment of Joseph Vittiglio as chief business and legal officer. Vittiglio most recently served as chief business and legal officer and corporate secretary at Bluebird Bio (BLUE).

bluebird bio (BLUE) announced the completion of its sale to funds managed by global investment firms Carlyle (CG) and SK Capital Partners. With the closing of the transaction, bluebird's common stock has ceased trading and will no longer be publicly listed. Carlyle and SK Capital have provided significant primary capital to support and scale bluebird's commercial delivery of gene therapies for patients with sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy. David Meek, who became Chief Executive Officer of bluebird at close, said, "Today marks the beginning of a new era for bluebird as its go-forward financial backing and leadership team will better enable all stakeholders to realize the full potential of our revolutionary therapies. Historically, bluebird has excelled as a scientific innovator and should be very proud of the many achievements it has delivered to patients. Our vision is to further that legacy of scientific excellence while improving the commercial execution of our approved products to rapidly expand access to lifechanging gene therapies."

PepGen (PEPG) announced the appointment of Kasra Kasraian as CTO. Kasraian brings over 25 years of experience in product and process development, CMC strategy, and technical operations, spanning small and large molecules, as well as cell and gene therapies. Kasraian joins PepGen from Bluebird Bio (BLUE), where he held various roles of increasing responsibility.